ID   ZR-75-27
AC   CVCL_5612
DR   Wikidata; Q54996118
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   PubMed=688225;
CC   Doubling time: 144 hours, at 14th passage (PubMed=688225).
CC   Derived from metastatic site: Pleural effusion.
DI   NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_1661 ! ZR-75-30
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-07-19; Version: 12
//
ID   ZR-75-30
AC   CVCL_1661
SY   ZR75-30; ZR7530
DR   BTO; BTO:0004915
DR   CLO; CLO_0009728
DR   EFO; EFO_0001263
DR   CLDB; cl4822
DR   CLDB; cl4823
DR   CLDB; cl4824
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-TABM-157
DR   ATCC; CRL-1504
DR   BCRC; 60056
DR   BioSample; SAMN03471856
DR   BioSample; SAMN10988534
DR   CCLE; ZR7530_BREAST
DR   CCRID; 3111C0001CCC000240
DR   CCRID; 3131C0001000700060
DR   CCRID; 3131C0001000700203
DR   CCRID; 3131C0001001200003
DR   CCRID; 3142C0001000000053
DR   CCTCC; GDC0054
DR   Cell_Model_Passport; SIDM00971
DR   ChEMBL-Cells; CHEMBL3308094
DR   ChEMBL-Targets; CHEMBL1075613
DR   Cosmic; 687504
DR   Cosmic; 871160
DR   Cosmic; 877444
DR   Cosmic; 894095
DR   Cosmic; 904399
DR   Cosmic; 909907
DR   Cosmic; 921977
DR   Cosmic; 949194
DR   Cosmic; 979716
DR   Cosmic; 1046953
DR   Cosmic; 1047719
DR   Cosmic; 1136346
DR   Cosmic; 1152523
DR   Cosmic; 1287913
DR   Cosmic; 1289422
DR   Cosmic; 1571790
DR   Cosmic; 1603230
DR   Cosmic; 2165016
DR   Cosmic-CLP; 909907
DR   DepMap; ACH-000828
DR   ECACC; 88113004
DR   GDSC; 909907
DR   GEO; GSM69200
DR   GEO; GSM73747
DR   GEO; GSM115121
DR   GEO; GSM217611
DR   GEO; GSM219946
DR   GEO; GSM274678
DR   GEO; GSM344379
DR   GEO; GSM344429
DR   GEO; GSM350533
DR   GEO; GSM421898
DR   GEO; GSM783957
DR   GEO; GSM847450
DR   GEO; GSM847510
DR   GEO; GSM844727
DR   GEO; GSM844726
DR   GEO; GSM887751
DR   GEO; GSM888846
DR   GEO; GSM984235
DR   GEO; GSM1053719
DR   GEO; GSM1172909
DR   GEO; GSM1173005
DR   GEO; GSM1238138
DR   GEO; GSM1401666
DR   GEO; GSM1661991
DR   GEO; GSM1670589
DR   IARC_TP53; 21112
DR   LiGeA; CCLE_237
DR   LINCS_HMS; 50575
DR   LINCS_LDP; LCL-1322
DR   PharmacoDB; ZR7530_1690_2019
DR   Wikidata; Q54996119
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   PubMed=688225;
RX   PubMed=3335022;
RX   PubMed=11044355;
RX   PubMed=11414198;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=17157791;
RX   PubMed=19582160;
RX   PubMed=19593635;
RX   PubMed=20070913;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=23151021;
RX   PubMed=23260012;
RX   PubMed=23601657;
RX   PubMed=24009699;
RX   PubMed=24094812;
RX   PubMed=24176112;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=23260012;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
WW   http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/ZR-75-30.html
WW   http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   http://tcpaportal.org/mclp/
WW   http://www.cellresource.cn/fdetail.aspx?id=240
WW   http://www.cellresource.cn/fdetail.aspx?id=628
WW   http://www.cellresource.cn/fdetail.aspx?id=821
WW   http://www.cellresource.cn/fdetail.aspx?id=1584
WW   http://www.cellresource.cn/fdetail.aspx?id=2096
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: GrayJW Breast Cancer Cell Line Panel.
CC   Part of: ICBP43 breast cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Doubling time: 110 hours, at 17th passage (PubMed=688225); 60 hours (PubMed=25984343); 324.46 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   HLA typing: A*23:01,03:01; B*07:02,35:08; C*04:01,07:02; DQB1*06:04,06:04 (PubMed=25960936).
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Sequence variation: APPBP2-PHF20L1 in-frame gene fusion (PubMed=23260012).
CC   Sequence variation: BCAS3-HOXB9 gene fusion (PubMed=23260012).
CC   Sequence variation: COL14A1-SKAP1 in-frame gene fusion (PubMed=23260012).
CC   Sequence variation: DDX5-DEPTOR in-frame gene fusion (PubMed=23260012).
CC   Sequence variation: ERBB2-BCAS3 out of frame gene fusion (PubMed=23260012).
CC   Sequence variation: PLEC1-ENPP2 in-frame gene fusion (PubMed=23260012).
CC   Sequence variation: TAOK1-PCGF2 in-frame gene fusion (PubMed=23260012).
CC   Sequence variation: TIAM1-NRIP1 in-frame gene fusion (PubMed=23260012).
CC   Sequence variation: TIMM23-ARHGAP32 out of frame gene fusion (PubMed=23260012).
CC   Sequence variation: TRPS1-LASP1 in-frame gene fusion (PubMed=23260012).
CC   Sequence variation: USP32-CCDC49 out of frame gene fusion (PubMed=23260012).
CC   Sequence variation: ZMYM4-OPRD1 out of frame gene fusion (PubMed=23260012).
CC   Sequence variation: Heterozygous for BRAF p.Ile326Thr (c.977T>C) (PubMed=19593635).
CC   Sequence variation: Homozygous for CDH1 p.Glu243Ter (c.727G>T) (PubMed=19593635).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: N-glycan profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=71.64%; Native American=0.74%; East Asian, North=3.41%; East Asian, South=0%; South Asian=0%; European, North=9.83%; European, South=14.38% (PubMed=30894373).
CC   Derived from metastatic site: Ascites.
ST   Source(s): ATCC; CCRID; Cosmic-CLP; ECACC; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 10,11
ST   D16S539: 9
ST   D18S51: 17
ST   D19S433: 13.2,14.2
ST   D21S11: 31
ST   D2S1338: 17,22
ST   D3S1358: 15,18
ST   D5S818: 12,13
ST   D7S820: 11,12
ST   D8S1179: 13,14
ST   FGA: 22
ST   Penta D: 2.2,10
ST   Penta E: 5,7
ST   TH01: 8,9
ST   TPOX: 10,11
ST   vWA: 18,19
DI   NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_5612 ! ZR-75-27
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-19; Version: 31
//
ID   ZR-75-9a1
AC   CVCL_5613
DR   Wikidata; Q54996121
RX   PubMed=2713239;
CC   Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC   Sequence variation: Homozygous for HRAS p.Glu162Lys (c.484G>A) (from parent cell line).
CC   Sequence variation: Homozygous for PTEN p.Leu108Arg (c.323T>G) (from parent cell line).
CC   Derived from metastatic site: Ascites.
DI   NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0588 ! ZR-75-1
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 13
//
ID   ZR-75-B
AC   CVCL_5614
SY   ZR75-B; ZR-75B; ZR-75b; ZR75B
DR   EFO; EFO_0001264
DR   ArrayExpress; E-TABM-157
DR   ArrayExpress; E-TABM-244
DR   Cosmic; 1136345
DR   Cosmic; 1176641
DR   DepMap; ACH-002331
DR   GEO; GSM1053730
DR   GEO; GSM1172910
DR   GEO; GSM1173006
DR   GEO; GSM1215271
DR   LINCS_HMS; 51096
DR   LINCS_LDP; LCL-2077
DR   PharmacoDB; ZR75B_1691_2019
DR   Wikidata; Q54996122
RX   PubMed=6178756;
RX   PubMed=17157791;
RX   PubMed=18516279;
RX   PubMed=24094812;
RX   PubMed=24162158;
RX   PubMed=24176112;
RX   PubMed=25960936;
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
CC   Part of: GrayJW Breast Cancer Cell Line Panel.
CC   Doubling time: 44.80 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   HLA typing: B*35:01,35:01; C*04:01,04:01; DQB1*05:01,05:01 (PubMed=25960936).
CC   Sequence variation: Homozygous for HRAS p.Glu162Lys (c.484G>A) (from parent cell line).
CC   Sequence variation: Homozygous for PTEN p.Leu108Arg (c.323T>G) (from parent cell line).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Misspelling: ZRB75; Occasionally.
CC   Derived from metastatic site: Ascites.
DI   NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0588 ! ZR-75-1
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 19
//
